Acarix

Acarix is a Malmö-based MedTech company pioneering non-invasive AI and acoustic diagnostics for coronary artery disease (CAD). Its CE-marked and FDA De Novo-cleared CADScor® System uses highly sensitive acoustic sensors and machine learning to rule out CAD with over 96% certainty, reducing unnecessary invasive procedures. Used in over 40,000 patients globally, Acarix won the 2025 Digital Innovation Award at the Global Cardiovascular Awards and achieved its first fixed US reimbursement milestone in 2025.